There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures.

The inaugural ADC Toxicity Summit is coming to Boston, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action, discuss shared challenges associated with translating in vivo toxicity data to the clinic, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market.

Take a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit.

Uniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists, through to nonclinical, translational, and clinical experts, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients.

3 reasons why you can’t miss out on joining include:

1. Select optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie
2. Hear how companies with commercially approved ADCs mitigated toxicities in the clinic, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute
3. Uncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb, Iksuda and Merck & Co

Harnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.